 |
|
|
|
This month we would like to know...
Has your organization begun to research the use of follow-on biologics (generics/biosimilars) and their potential impact on managing cost of care?
Vote in our survey, and see what other P&T committee members have to say.
 |
|
|
|
Contact Us
Click here to contact a Formulary editor.
Click here to contact a Formulary sales representative.
Click here to learn about direct mail, reprints and classifieds in Formulary.
Formulary
Digital Edition
Click here to view the current edition.
Click here to subscribe. |
|
|
|
|
|
|
Bias risk higher in industry-funded pediatric studies
A high proportion of pediatric, randomized controlled trials have a high risk for bias, particularly those that are industry-funded or involve assessment of behavioral/educational interventions, but trial registration is linked to less risk of bias, according to research published online July 12 in Pediatrics, HealthDay News reported. More... |
|
MPV4 vaccine not linked to Henoch-Schönlein purpura
Meningococcal polysaccharide vaccine (MPV4) does not appear to be associated with post-vaccination Henoch-Schönlein purpura in 16- to 20-year-olds, according to research published online July 12 in Pediatrics, HealthDay News reported. More... |
|
Lorcaserin linked to weight loss, maintenance
The use of lorcaserin, along with behavioral modification, is associated with weight loss and subsequent weight maintenance compared with placebo, according to a study published in the July 15 issue of the New England Journal of Medicine, HealthDay News reported. More... |
Naltrexone, bupropion combination helps individuals lose excess weight
Investigational combination treatment with sustained-release (SR) naltrexone and bupropion (Contrave, Orexigen Therapeutics)—plus lifestyle modification, appears effective in helping people lose 5% or more of their excess body weight, according to research published online July 30 in The Lancet, as reported by HealthDay News. More... |
OAD agents effective in reducing hemoglobin levels up to 1.5%
Oral antidiabetic (OAD) agents generally result in a maximum 1.5% drop in hemoglobin (Hb)A1C levels, with sulfonylureas and thiazolidinediones having a slightly more beneficial effect than other classes of oral agents, according to research published in the August issue of Diabetes Care, as reported by HealthDay News. More... |
Newer AEDs linked to self-harm, suicidal behavior
Patients taking newer antiepileptic drugs (AEDs) that are associated with a high risk of depression may have an elevated risk of self-harm or suicidal behavior, but other groups of AEDs do not appear to carry the same risk, according to research published in the July 27 issue of Neurology, as reported in HealthDay News. More... |
Hospital-acquired MRSA infections decline between 2005 and 2008
Infections with the deadly methicillin-resistant Staphylococcus aureus (MRSA) bacteria that begin in hospitals and other healthcare settings have declined 28% over a 4-year period, according to a new Centers for Disease Control and Prevention study of about 15 million people. The study was published in the Aug. 11 issue of the Journal of the American Medical Association, as reported by HealthDay News. More... |
FDA approves first-time generic Lovenox
No sooner does Sandoz begin shipments of the generic version, Sanofi-Aventis, manufacturer of Lovenox, files a lawsuit to prevent the approval of the generic. More... |
FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients
FDA approved increasing the length of therapy with Valcyte (valganciclovir hydrochloride) in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease, according to Genentech Inc. on Aug. 10. More... |
Novo Nordisk gets approval for 8-mg vial of NovoSeven RT
FDA has approved NovoSeven RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8-mg vial size, making the hemophilia A or B with inhibitors treatment available in 1-, 2-, 5-, and 8-mg vials, Novo Nordisk announced on Aug. 10. The 8-mg vial allows a rapid initiation and administration of the medication for those patients who need a larger dose. More... |
|
|
|
| In the Pipeline |
| FDA Pipeline Preview, July 2010 (Aspirin/esomeprazole, Meningococcal and Hib combination vaccine, Eslicarbazepine acetate, Tesamorelin, Ulipristal acetate, flibanserin, Alemtuzumab, COL-172, Ex vivo expanded cord blood, Naltrexone for extended-release injectable suspension, Eribulin mesylate) |
|
|
|
|
|
| |
